Shares of Genmab A/S (OTCMKTS:GNMSF – Get Free Report) hit a new 52-week low on Monday . The stock traded as low as $186.61 and last traded at $186.61, with a volume of 26 shares changing hands. The stock had previously closed at $187.73.
Genmab A/S Price Performance
The stock has a market cap of $12.67 billion, a PE ratio of 18.45 and a beta of 1.04. The stock’s fifty day moving average is $207.03 and its 200-day moving average is $230.86.
Genmab A/S Company Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Recommended Stories
- Five stocks we like better than Genmab A/S
- High Flyers: 3 Natural Gas Stocks for March 2022
- 3 Reasons Micron Stock Is Deeply Undervalued Right Now
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Inflation Persists, But So Do Stock Opportunities: Rally On
- What Are Dividend Contenders? Investing in Dividend Contenders
- Energy Transfer Fuels the Cloud: A Natural Gas Power Play
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
